Please provide your email address to receive an email when new articles are posted on . The FDA granted fast track designation to MCO-010 from Nanoscope Therapeutics for the treatment of retinitis ...

According to Aldeyra Therapeutics, a phase 2/3 trial of ADX-2191 in patients with retinitis pigmentosa is expected to begin in 2025. The Food and Drug Administration (FDA) has granted Fast Track ...

SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Today, Verana Health ®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), ...

Nanoscope Therapeutics Inc., a biotechnology company focused on developing and commercializing novel, disease‑agnostic therapies for patients with photoreceptor loss and vision impairment due to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The investigational cell therapy is designed to replace ...

STOCKHOLM — Trial results are demonstrating the safety and effectiveness of a novel gene modifier therapy for treating retinitis pigmentosa associated with NR2E3 and RHO mutations. Researchers ...

Science and Technology Honors Program, University of Alabama at Birmingham, Birmingham, AL, USA School of Health Professions Honors Program, University of Alabama at Birmingham, Birmingham, AL, USA ...

Scientists have identified two non-retinoid compounds that may be able to treat retinitis pigmentosa (RP), a group of inherited eye diseases that cause blindness. The compounds were discovered by ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds, described in a study published January 14 th in the open-access ...

Retinitis pigmentosa, a degenerative genetic disease of the eye, is characterized by progressive vision loss, usually leading to blindness. In some patients, structural defects in the photoreceptor ...